The Jerusalem PostHouthis gain ground near Red Sea shipping route as Yemen government redeploys forces - analysisInquirerDTI, FDA, ex-AMLC execs sought to testify on Duterte businessesPunchPolice arrest eight after APC, NDC clash in KanoDaily MaverickGRASSROOTS MOVEMENT: ‘Matter of life and death’ — activists reject COP31 ‘pretence’, demand real climate actionZDF heuteAktuelle Pressemitteilungen des ZDFThe South AfricanBrace for extreme heat as temperatures soar into the 40s in two provincesComplete SportsSPORTS PLANET Podcast…EPISODE 162: Mauricio Pochettino Appointment As Manchester United ManagerGlobal NewsCanada’s inflation was steady at 3.1 per cent in October, StatCan saysDeadlineDeal (Nearly) Done? UK Actors Union Equity Urges Members To Vote “Yes” On Final Offer From Pact Including Streamer Compensation, Pay Bumps & “Groundbreaking” AI ProvisionsABC News2027 Grammy nominations: Live updatesRai NewsCos'è la banca digitale Revolut senza sportelli e senza costi delle banche tradizionaliRTL BoulevardWilliam en Catherine nemen de metro in Mumbai
The Daily Newsstand · Free, Always
Monday, November 16, 2026

Moleculin Biotech reports Q3 results

Translate
  • Moleculin Biotech press release (MBRX): Q3 Diluted loss per share of $9.59 vs. $340.43 Y/Y.
  • Cash and cash equivalents totaled $7.3M as of September 30, 2026, compared with $8.9M as of December 31, 2025.
  • Net loss of $6.5M vs. $25.4M Y/Y, down 74% Y/Y, primarily reflecting the absence of a $20.6M non-cash loss on issuance of warrant liabilities in the prior-year period.

  • R&D expenses of $4.5M, up 20% Y/Y.

More on Moleculin Biotech

View the original on Seeking Alpha →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.